MRNA · News · 20260731N
Litigation Settlement Exposure
Moderna, Inc. · 2026-07-31 · Importance 71 · Surprise 60 · In source text
Moderna recognized approximately $884 million of royalties related to a $950 million patent settlement with Arbutus and Genevant. The royalties materially increased cost of sales and contributed to a six-month 2026 net loss of approximately $2.125 billion. The settlement represents a significant cash and earnings burden relative to Moderna’s $145 million second-quarter revenue.
Key facts
- Moderna recorded $884 million in royalties that primarily drove an increase in cost of sales related to a $950 million patent settlement with Arbutus and Genevant. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -609.7% | Moderna recorded $884 million in royalties that primarily drove an increase in cost of sales related to a $950 million patent settlement… |
| net_income | negative | realized | -609.7% | Moderna recorded $884 million in royalties that primarily drove an increase in cost of sales related to a $950 million patent settlement… |